Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis

被引:3
|
作者
Chen, Bo [1 ]
Ji, Su-Qiong [1 ]
Shen, Fan [1 ]
Tian, Dai-Shi [1 ]
Bu, Bi-Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430030, Peoples R China
关键词
Relapse-associated worsening; Progression independent of relapse activity; Relapsing-onset multiple sclerosis; Mediation analysis; Onset age; NATURAL-HISTORY; CLINICAL-COURSE; AGE; OCRELIZUMAB; PROGRESSION; INTERFERON; PLACEBO; MODELS;
D O I
10.1016/j.msard.2022.103555
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The neurological disability accumulation in patients with relapsing-onset multiple sclerosis (MS) is commonly attributed to relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). Using a mediation model, this research aimed to investigate and quantify the contributions of RAW and PIRA to the overall disability accrual.Methods: Clinical data, containing Expanded Disability Status Scale (EDSS) scores, duration, attack number, and demographics, were collected from 121 patients with relapsing-onset MS in China and included in the mediation model. Two phases were defined: an early phase, from the clinical onset to EDSS 3, and a later phase, greater than EDSS 3.Results: Clinical attack number partly mediated the relationship between duration and neurological disability (Duration-* Attack-* EDSS score) only in the early phase, with the ratio of indirect (RAW) to total effect of 0.414; while this mediator effect became negligible (<10%) in the later phase, with a predominating direct effect (PIRA). Onset age positively correlated with EDSS scores during the early stage, independent of the clinical attack number (the direct effect was significant, but the indirect effect was not), while this association was insignificant later. Besides, compared to females, male patients appeared to relapse less frequently before reaching EDSS 3 but were vulnerable to an accelerated progression after that.Conclusions: In relapsing-onset MS, PIRA is the major contributor to the irreversible disability accrual throughout the whole disease course, albeit RAW is also partly involved during the early stage. The correlations between the disabled outcome and the onset age or sex vary in different phases.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] The 'Coronavirus disease of 2019' is associated with disability worsening in patients with multiple sclerosis
    Peeters, G.
    Van Remoortel, A.
    Nagels, G.
    Van Schependom, J.
    D'haeseleer, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 211 - 212
  • [22] Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis
    Kappos, L.
    Wolinsky, J. S.
    Giovannoni, G.
    Arnold, D. L.
    Lublin, F.
    Wang, Q.
    Model, F.
    Wei, W.
    Garren, H.
    Manfrini, M.
    Belachew, S.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 309 - 310
  • [23] Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis
    Montalban, Xavier
    Cohen, Jeffrey A.
    Comi, Giancarlo
    Coyle, Patricia K.
    Kappos, Ludwig
    Li, Bingbing
    Sfikas, Nikolaos
    Willi, Roman
    Haring, Dieter A.
    Merschhemke, Martin
    Hauser, Stephen L.
    NEUROLOGY, 2020, 94 (15)
  • [24] Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis
    Kappos, Ludwig
    Montalban, Xavier
    Coyle, Patricia
    Nicholas, Jacqueline
    Meuth, Sven
    Li, Bingbing
    Ramanathan, Krishnan
    Su, Wendy
    Willi, Roman
    Haering, Dieter A.
    Hauser, Stephen
    NEUROLOGY, 2021, 96 (15)
  • [25] Retinal ganglion cell loss is associated with future disability worsening in early relapsing remitting multiple sclerosis
    Wauschkuhn, J.
    Buenrostro, G. Solorza
    Aly, L.
    Asseyer, S.
    Wicklein, R.
    Hartberger, J. M.
    Ruprecht, K.
    Muehlau, M.
    Schmitz-Huebsch, T.
    Chien, C.
    Berthele, A.
    Brandt, A. U.
    Korn, T.
    Paul, F.
    Hemmer, B.
    Zimmermann, H. G.
    Knier, B.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 571 - 572
  • [26] Metabolomics associated with relapse rate and disability progression in relapse remitting multiple sclerosis patients
    Kitsos, D.
    Sideri, E.
    Chondrogianni, M.
    Tsivgoulis, A.
    Zompola, C.
    Thomaidis, N.
    Voumvourakis, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 938 - 938
  • [27] Effect of ofatumumab treatment on disability progression independent of relapse activity in patients with relapsing multiple sclerosis
    Kappos, L.
    Montalban, X.
    Cohen, J. A.
    Comi, G.
    Coyle, P. K.
    Li, B.
    Sfikas, N.
    Willi, R.
    Haring, D. A.
    Merschhemke, M.
    Hauser, S. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 47 - 47
  • [28] Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
    Chang, Ih
    Kappos, Ludwig
    Giovannoni, Gavin
    Calabresi, Peter A.
    Sandrock, Alfred
    Cheng, Wenting
    Xiao, Shan
    Riester, Katherine
    Belachew, Shibeshih
    Deykin, Aaron
    Zhu, Bing
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (14) : 2263 - 2273
  • [29] Retinal ganglion cell loss is associated with future disability worsening in early relapsing-remitting multiple sclerosis
    Wauschkuhn, Josephine
    Buenrostro, Gilberto Solorza
    Aly, Lilian
    Asseyer, Susanna
    Wicklein, Rebecca
    Hartberger, Julia Maria
    Ruprecht, Klemens
    Muehlau, Mark
    Schmitz-Huebsch, Tanja
    Chien, Claudia
    Berthele, Achim
    Brandt, Alexander U. U.
    Korn, Thomas
    Paul, Friedemann
    Hemmer, Bernhard
    Zimmermann, Hanna G. G.
    Knier, Benjamin
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (04) : 982 - 990
  • [30] Oxidative stress is associated with disability in relapsing-remitting multiple sclerosis patients
    Oliveira, S. R.
    Kallaur, A. P.
    Simao, A. N. C.
    Kaimen-Maciel, D. R.
    Lopes, J.
    Panis, C.
    Pereira, W. L. C. J.
    de Andrade, R. M.
    Reiche, E. M. V.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 343 - 343